Now that the Food and Drug Administration has authorized remdesivir for emergency use in seriously ill COVID-19 patients, the experimental drug is another step closer to full approval. That’s when most drugs get price tags. Gilead Sciences, which makes remdesivir, is donating its initial supply of 1.5 million doses, but the company has signaled it will need to start charging for the drug to make production sustainable. It’s unclear when that decision might be made. “It’s hard to imagine a situation in which there will be more public scrutiny,” said Michael Carrier, a professor at Rutgers School of Law who specializes in antitrust and pharmaceuticals. “On the one hand, Gilead will try to recover its R&D in an atmosphere in which it is able to potentially make a lot of money. On the other hand, the pressure will be intense not to charge what’s viewed as too high a price.” To read the full story.
- OPINION: The health-care industry doesn’t want to talk about this single word
- Rutgers’ new COVID-19 rapid test can identify variants
- Dr. Johnson featured on NJ Spotlight news: Why is vaccine equity still lagging among NJ’s Black and brown residents?
- NJ ACTS TL1 Fellowship – Applications Available
- Join NJ ACTS Special Populations Core for a Special Webinar, April 16th at 12pm